Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 15, 2026, 4:52 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Heartburn Clear all
Not listed Phase 4 Interventional

Folic Acid in Pediatric Inflammatory Bowel Disease

NCT03860012
View directory record Official record
Conditions
Inflammatory Bowel Diseases
Interventions
Folic Acid
Drug
Lead sponsor
Le Bonheur Children's Hospital
Other
Eligibility
2 Years to 21 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 28, 2019 · Synced Sep 15, 2026, 4:52 PM EDT
Not listed Phase 1Phase 2 Interventional

Comparison of Nexium Versus Secretol in the Healing and Controlling of Symptoms in GERD Patients With Severe EE.

NCT01129713
View directory record Official record
Conditions
Gastroesophageal Reflux Disease (GERD), Heartburn, Indigestion
Interventions
Secretol, Nexium
Drug
Lead sponsor
Effexus Pharmaceutical
Industry
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 4, 2014 · Synced Sep 15, 2026, 4:52 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Vecam 40/300 and Vecam 20/300 Compared to Omeprazole 20 mg on Gastric pH

NCT00818870
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
Omeprazole, Vecam
Drug
Lead sponsor
Vecta Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 26, 2010 · Synced Sep 15, 2026, 4:52 PM EDT
Completed Phase 4 Interventional Results available

An Exploratory Study of the Safety and Efficacy of Prophylactic Immunomodulatory Treatment in Myozyme-naive Cross-Reacting Immunologic Material (CRIM[-]) Patients With Infantile-Onset Pompe Disease

NCT00701129
View directory record Official record
Conditions
Pompe Disease, Glycogen Storage Disease Type II
Interventions
Alglucosidase Alfa, Methotrexate, Rituximab
Biological · Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
Not listed
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
2
States / cities
Louisville, Kentucky • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 12, 2014 · Synced Sep 15, 2026, 4:52 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Skin Maturation in Premature Infants

NCT01619228
View directory record Official record
Conditions
Premature Birth of Newborn
Interventions
Not listed
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
24 Weeks to 43 Weeks
Enrollment
107 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
2
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 9, 2020 · Synced Sep 15, 2026, 4:52 PM EDT
Completed Phase 2 Interventional Results available

Validation of Patient-reported Outcomes Measures for the Assessment of Gastroesophageal Reflux Disease (GERD) Symptoms

NCT00703534
View directory record Official record
Conditions
GERD, Acid Reflux Disease, Heartburn, Regurgitation
Interventions
AZD3355, Placebo, Gelusil®
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
478 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
84
States / cities
Athens, Alabama • Tucson, Arizona • Little Rock, Arkansas + 81 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2011 · Synced Sep 15, 2026, 4:52 PM EDT
Completed No phase listed Observational

A Study to Investigate Use Patterns and Safety in Simulated Actual Over-the-counter (OTC) Use of Rabeprazole Sodium for the Treatment of Heartburn Symptoms

NCT01286194
View directory record Official record
Conditions
Frequent Heartburn
Interventions
Rabeprazole sodium
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
33
States / cities
Scottsdale, Arizona • Griffin, Georgia • Lawrenceville, Georgia + 29 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2011 · Synced Sep 15, 2026, 4:52 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

In Vivo Anatomy, Physiology, Mechanics and Function of the Lower Esophageal Sphincter

NCT00737802
View directory record Official record
Conditions
GERD, Barretts Esophagus
Interventions
Not listed
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 75 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Feb 21, 2019 · Synced Sep 15, 2026, 4:52 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Dexlansoprazole Modified Release Formulation to Treat Heartburn

NCT00251758
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
Dexlansoprazole MR, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
908 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
99
States / cities
Anniston, Alabama • Hueytown, Alabama • Huntsville, Alabama + 96 more
Source: ClinicalTrials.gov public record
Updated May 17, 2010 · Synced Sep 15, 2026, 4:52 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Dexlansoprazole Delayed-Release Capsules for Healing of Erosive Esophagitis and Maintenance of Healed Erosive Esophagitis and Relief of Heartburn in Adolescents

NCT01642615
View directory record Official record
Conditions
Gastroesophageal Reflux Disease, Erosive Esophagitis
Interventions
Dexlansoprazole, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
12 Years to 17 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
32
States / cities
Huntsville, Alabama • Mobile, Alabama • Phoenix, Arizona + 29 more
Source: ClinicalTrials.gov public record
Updated May 26, 2015 · Synced Sep 15, 2026, 4:52 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Dexlansoprazole Delayed-Release Capsules in Treating Symptomatic Non-Erosive Gastroesophageal Reflux Disease in Adolescents

NCT01642602
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
Dexlansoprazole
Drug
Lead sponsor
Takeda
Industry
Eligibility
12 Years to 17 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
35
States / cities
Huntsville, Alabama • Mobile, Alabama • Phoenix, Arizona + 32 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2014 · Synced Sep 15, 2026, 4:52 PM EDT
Completed Phase 1 Interventional

Can E-cadherin Found in Tissue/Blood be Valuable in Identifying & Monitoring Patients With Post-proton Pump Inhibitor (PPI)-Responsive Heartburn

NCT01149395
View directory record Official record
Conditions
Heartburn, Gastroesophageal Reflux Disease
Interventions
Dexlansoprazole
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 18, 2016 · Synced Sep 15, 2026, 4:52 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate Vonoprazan Concentrations in Breast Milk of Healthy Lactating Women Receiving Vonoprazan 20 mg Once Daily or Vonoprazan 20 mg Twice Daily

NCT06391177
View directory record Official record
Conditions
Erosive Esophagitis, Heartburn, Symptomatic Nonerosive Gasroesophageal Reflux Disease, Helicobacter Pylori Infection
Interventions
Vonoprazan
Drug
Lead sponsor
Phathom Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Mar 24, 2025 · Synced Sep 15, 2026, 4:52 PM EDT
Completed Not applicable Interventional

Upset Stomach Relief for Mild and Moderate Indigestion and Heartburn

NCT04153552
View directory record Official record
Conditions
Indigestion, Heartburn
Interventions
HLNatural, Inc. Upset Stomach Relief
Dietary Supplement
Lead sponsor
Hawthorne Effect Inc.
Other
Eligibility
18 Years and older
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 14, 2021 · Synced Sep 15, 2026, 4:52 PM EDT
Completed Phase 2 Interventional

Multi-Center Study of Panosyl-Isomaltooligosaccharides Adjunctive to PPI Therapy to Treat GERD

NCT05556824
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
MHS-1031, Placebo
Drug · Other
Lead sponsor
Microbiome Health Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
18
States / cities
Phoenix, Arizona • Los Angeles, California • Lake City, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2026 · Synced Sep 15, 2026, 4:52 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Remote Guided Caffeine Reduction

NCT04560595
View directory record Official record
Conditions
Caffeine Dependence, Anxiety, Sleep Disturbance, Gastrointestinal Dysfunction, Sleep Initiation and Maintenance Disorders, Caffeine; Sleep Disorder, Caffeine, Caffeine-Induced Anxiety Disorder, Caffeine Withdrawal, Caffeine-Induced Sleep Disorder, Without Use Disorder, Caffeine Abuse, Insomnia, Anxiety Disorders, Sleep Disorder, Heartburn, Diarrhea
Interventions
Caffeine Reduction Manual
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 75 Years
Enrollment
109 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 13, 2025 · Synced Sep 15, 2026, 4:52 PM EDT
Not listed No phase listed Observational

Decision Aid for Gastroesophageal Reflux Disease Management

NCT01641887
View directory record Official record
Conditions
Gastroesophageal Reflux Disease, Esophageal Cancer, Barrett's Esophagus
Interventions
Decision Aid
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 3, 2013 · Synced Sep 15, 2026, 4:52 PM EDT
Completed Phase 2 Interventional

ADX10059 as an add-on Therapy to Proton Pump Inhibitors (PPIs) in Patients With Gastroesophageal Reflux (GERD)

NCT00810485
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
ADX10059, ADX10059 Matching Placebo
Drug
Lead sponsor
Addex Pharma S.A.
Industry
Eligibility
18 Years to 70 Years
Enrollment
298 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
28
States / cities
Little Rock, Arizona • Tucson, Arizona • Anaheim, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2012 · Synced Sep 15, 2026, 4:52 PM EDT
Completed Phase 4 Interventional Results available

Pilot Study To Investigate The Association Between Acid Control And Heartburn Symptoms After Proton Pump Inhibitor Treatment

NCT02708355
View directory record Official record
Conditions
Heartburn
Interventions
Esomeprazole 20 mg, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
22 Years to 65 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
2
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Apr 18, 2017 · Synced Sep 15, 2026, 4:52 PM EDT
Completed Phase 4 Interventional

An Open-Label Study of Once-Daily Oral Administration of Esomeprazole 40 mg in Patients With Symptoms of Gastroesophageal Reflux Disease (GERD)

NCT00242736
View directory record Official record
Conditions
GERD
Interventions
Esomeprazole
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
25
States / cities
Alabaster, Alabama • Mobile, Alabama • Tucson, Arizona + 22 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2009 · Synced Sep 15, 2026, 4:52 PM EDT
Not listed Not applicable Interventional

Nasogastric/Orogastric Tube Placement Verification Study Using RightSpot pH Indicator to Verify Gastric Acidity

NCT01561729
View directory record Official record
Conditions
Small Bowel Obstruction, Gastrointestinal Hemorrhage
Interventions
RightSpot pH Indicator, Chest radiograph
Device · Radiation
Lead sponsor
RightBio Metrics
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Nov 3, 2014 · Synced Sep 15, 2026, 4:52 PM EDT
Completed Phase 4 Interventional Results available

The CALIBER Study Randomized Controlled Trial of LINX Versus Double-Dose Proton Pump Inhibitor Therapy for Reflux Disease

NCT02505945
View directory record Official record
Conditions
GERD Gastroesophageal Reflux Disease
Interventions
Omeprazole, LINX Reflux Management System
Drug · Device
Lead sponsor
Torax Medical Incorporated
Industry
Eligibility
21 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
21
States / cities
Mobile, Alabama • Heber Springs, Arkansas • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2019 · Synced Sep 15, 2026, 4:52 PM EDT
Completed Phase 3 Interventional Results available

Efficacy of Esomeprazole in Patients With Frequent Heartburn

NCT01370525
View directory record Official record
Conditions
Heartburn
Interventions
Esomeprazole
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
10
States / cities
Sacramento, California • Seminole, Florida • Meridian, Idaho + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2013 · Synced Sep 15, 2026, 4:52 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

Effect of Pantoprazole 40mg Daily vs Placebo on Power Spectral Analysis of the Sleep EEG of Patients With GERD.

NCT00674245
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
Pantoprazole, placebo
Drug
Lead sponsor
Southern Arizona VA Health Care System
Federal
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 18, 2010 · Synced Sep 15, 2026, 4:52 PM EDT